TYBAMATE

First approved in 1965

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H26N2O4
Molecular Weight	274.3565
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCNC(=O)OCC(C)(CCC)COC(N)=O

InChI

InChIKey=PRBORDFJHHAISJ-UHFFFAOYSA-N

InChI=1S/C13H26N2O4/c1-4-6-8-15-12(17)19-10-13(3,7-5-2)9-18-11(14)16/h4-10H2,1-3H3,(H2,14,16)(H,15,17)

HIDE SMILES / InChI

Molecular Formula	C13H26N2O4
Molecular Weight	274.3565
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5897789 | https://www.ncbi.nlm.nih.gov/pubmed/14165722

Tybamate is a minor tranquilizer that is chemically and pharmacologically related to meprobamate. It is useful in treating anxiety and tension associated with psychoneurotic disorders.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Depression 235 Sources: https://books.google.ru/books?id=wNgjTA77neAC&pg=PA5&lpg=PA5&dq=Solacen+TYBAMATE	Primary		Approved 8429	Solacen Approved Use Anxiolytic Launch Date 1964

C_max

Value	Dose	Co-administered	Analyte	Population
10 μg/mL EXPERIMENT https://www.sciencedirect.com/science/article/pii/S0099542808600258	15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		TYBAMATE serum	Canis lupus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
3 h EXPERIMENT https://www.sciencedirect.com/science/article/pii/S0099542808600258	15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		TYBAMATE serum	Canis lupus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
350 mg 4 times / day steady, oral Highest studied dose Dose: 350 mg, 4 times / day Route: oral Route: steady Dose: 350 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/	unhealthy, 22 - 41 years Health Status: unhealthy Condition: psychosomatic symptoms in infertility patients Age Group: 22 - 41 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/	Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/
350 mg 3 times / day steady, oral Recommended Dose: 350 mg, 3 times / day Route: oral Route: steady Dose: 350 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/	unhealthy, 22 - 41 years n = 17 Health Status: unhealthy Condition: psychosomatic symptoms in infertility patients Age Group: 22 - 41 years Sex: F Population Size: 17 Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/	Other AEs: Drowsiness, Dizziness... Other AEs: Drowsiness (7 patients) Dizziness (6 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/
750 mg 4 times / day steady, oral Highest studied dose Dose: 750 mg, 4 times / day Route: oral Route: steady Dose: 750 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14138831/	unhealthy, 49.5 years n = 66 Health Status: unhealthy Condition: anxious neurotic Age Group: 49.5 years Sex: M+F Population Size: 66 Sources: https://pubmed.ncbi.nlm.nih.gov/14138831/	Other AEs: Tachycardia, Dry mouth... Other AEs: Tachycardia (1 patient) Dry mouth (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/14138831/

AEs

AE	Significance	Dose	Population
Dizziness	6 patients	350 mg 3 times / day steady, oral Recommended Dose: 350 mg, 3 times / day Route: oral Route: steady Dose: 350 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/	unhealthy, 22 - 41 years n = 17 Health Status: unhealthy Condition: psychosomatic symptoms in infertility patients Age Group: 22 - 41 years Sex: F Population Size: 17 Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/
Drowsiness	7 patients	350 mg 3 times / day steady, oral Recommended Dose: 350 mg, 3 times / day Route: oral Route: steady Dose: 350 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/	unhealthy, 22 - 41 years n = 17 Health Status: unhealthy Condition: psychosomatic symptoms in infertility patients Age Group: 22 - 41 years Sex: F Population Size: 17 Sources: https://pubmed.ncbi.nlm.nih.gov/4890013/
Dry mouth	1 patient	750 mg 4 times / day steady, oral Highest studied dose Dose: 750 mg, 4 times / day Route: oral Route: steady Dose: 750 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14138831/	unhealthy, 49.5 years n = 66 Health Status: unhealthy Condition: anxious neurotic Age Group: 49.5 years Sex: M+F Population Size: 66 Sources: https://pubmed.ncbi.nlm.nih.gov/14138831/
Tachycardia	1 patient	750 mg 4 times / day steady, oral Highest studied dose Dose: 750 mg, 4 times / day Route: oral Route: steady Dose: 750 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14138831/	unhealthy, 49.5 years n = 66 Health Status: unhealthy Condition: anxious neurotic Age Group: 49.5 years Sex: M+F Population Size: 66 Sources: https://pubmed.ncbi.nlm.nih.gov/14138831/

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY554377	https://www.001chemical.com/chem/4268-36-4
ABI Chem	AC1L2FWM
Ambinter	Amb22734893	http://www.ambinter.com/reference/22734893
Aurora Fine Chemicals LLC	A17.944.630	http://online.aurorafinechemicals.com/info?ID=A17.944.630
BOC Sciences	4268-36-4
ChemMol	99094824	http://www.chemmol.com/chemmol/99094824.html
Chemieliva Pharmaceutical Co., Ltd	PBCM1305851
Compound Cloud	20266
HongKong Chemhere	SCA31878
LGC Standards	LGCFOR1626.00	https://www.lgcstandards.com/US/en/p/LGCFOR1626.00
Molcore	MC554377	https://www.molcore.com/product/4268-36-4
NCI Plated 2007	172126
NovoSeek	20266
Sigma Aldrich	PH003059
Sigma Aldrich	PH003059\|ALDRICH
Sigma-Aldrich	PH003059_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph003059
Smolecule	S546095	http://www.smolecule.com/products/s546095
THE BioTek	bt-284464	https://www.thebiotek.com/product/inhibitors/bt-284464
ZINC	ZINC000001692922	http://zinc15.docking.org/substances/ZINC000001692922
ZINC	ZINC000002037958	http://zinc15.docking.org/substances/ZINC000002037958

PubMed

Title	Date	PubMed
TYBAMATE, A NEW TRANQUILIZER.	1963 Nov	14051244
PHARMACOLOGIC PROPERTIES OF A NEW TRANQUILIZING AGENT, 2-METHYL-2-PROPYLTRIMETHYLENE BUTYLCARBAMATE CARBAMATE (TYBAMATE).	1964	14165722
Evaluation of a new minor tranquilizer: tybamate (Solacen).	1965 Dec 6	5897789
Solacen-tybamate.	1966 Dec	5180347

Sample Use Guides

In Vivo Use Guide

The usual dose for adults is 0.75 to 2 gm per day. Daily doses larger than 3 gm should not be used.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:36:01 GMT 2023` Edited by `admin` on `Fri Dec 15 15:36:01 GMT 2023`
Record UNII	3875LLL8M8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TYBAMATE

Official Name

English

W 713

Code

English

Tybamate [WHO-DD]

Common Name

English

2-(Hydroxymethyl)-2-methylpentyl butylcarbamate carbamate

Systematic Name

English

TYBAMATE [HSDB]

Common Name

English

SOLACEN

Brand Name

English

TYBAMATE [MI]

Common Name

English

W-713

Code

English

NSC-172126

Code

English

CARBAMIC ACID, BUTYL-, 2-(((AMINOCARBONYL)OXY)METHYL)-2-METHYLPENTYL ESTER

Common Name

English

TYBAMATE [USAN]

Common Name

English

tybamate [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29756